Aveanna Q2 revenue up 6.5% to $472M; raises full-year guidance

Aveanna Healthcare Holdings, Inc.

2023-Q2 EPS reported -$0.03 revenue$938,358,000

Revenue $471.9M (+6.5% YoY); net income $25.6M vs loss $473.9M (absence of $470.2M goodwill impairment).
Adjusted EBITDA $35.8M (-3.2% YoY, +25.6% seq.); margin 7.6% vs 8.3% prior year.
Full-year 2023 revenue guidance raised to $1,850M-$1,860M; Adj. EBITDA guidance $132M-$135M.
PDS segment revenue up $29.6M; HHH segment down $6.0M; Medical Solutions up $5.3M.
Cash $28M; revolver undrawn with $162M capacity; securitization facility extended to July 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Aveanna Healthcare Holdings, Inc. reported three and six-month periods ended July 1, 2023 results: revenue $471.9 million, net income $25.6 million, EPS $0.13. Guidance raised.

Period: three and six-month periods ended July 1, 2023
Revenue: $471.9 million
Net income: $25.6 million
EPS: $0.13
Guidance: raised
Result: reported results

Exact text from the filing

Revenue was $471.9 million, a 6.5% increase over the prior year o Gross margin increased 7.0% to $155.3 million, compared to Q2 2022 • Net income was $25.6 million, compared to net loss of $473.9 million in the comparable prior year period o Adjusted EBITDA was $35.8 million, a sequential increase of 25.6% and a 3.2% decrease as compared to the prior year • Full year 2023 revenue guidance raised to a range of $1,850 million to $1,860 million o Full year 2023 Adjusted EBITDA guidance raised to a range of $132 million to $135 million

View on SEC.gov

Browse all earnings releases →

Aveanna Healthcare Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040917

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.